Literature DB >> 12609306

Psychiatric comorbidity in patients with developmental disorders and epilepsy: a practical approach to its diagnosis and treatment.

Andres M. Kanner1.   

Abstract

Psychiatric comorbidity in patients with developmental disorders and epilepsy (PDDEs) is relatively frequent. The majority of its pharmacological treatment has consisted of the use of neuroleptic drugs in an attempt to control behavioral disturbances, despite the fact that these symptoms may often mask underlying psychiatric disorders such as anxiety and depression, which require other types of psychotropic drugs. In this article, we review the pathogenic mechanisms that mediate the clinical manifestations of psychiatric disorders in PDDEs, highlight diagnostic strategies that may help in elucidating the correct psychiatric diagnosis, and review the psychopharmacological treatments available.

Entities:  

Year:  2002        PMID: 12609306     DOI: 10.1016/s1525-5050(02)00536-x

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Brief Report: Factors Associated with Emergency Department Visits for Epilepsy Among Children with Autism Spectrum Disorder.

Authors:  Wanqing Zhang; Grace Baranek; Brian Boyd
Journal:  J Autism Dev Disord       Date:  2018-05

Review 2.  Treatment models for treating patients with combined mental illness and developmental disability.

Authors:  Ervin Davis; L Jarrett Barnhill; Sy Atezaz Saeed
Journal:  Psychiatr Q       Date:  2008-08-23

Review 3.  Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-11-24       Impact factor: 3.022

Review 4.  Depression and anxiety in people with epilepsy.

Authors:  Oh-Young Kwon; Sung-Pa Park
Journal:  J Clin Neurol       Date:  2014-07-03       Impact factor: 3.077

5.  Clinical presentation of anxiety among patients with epilepsy.

Authors:  M López-Gómez; M Espinola; J Ramirez-Bermudez; I E Martinez-Juarez; A L Sosa
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.